Epigenetic alterations in glioblastomas: Diagnostic, prognostic and therapeutic relevance
International Journal of Cancer · 2023-08 · 153 (3) · 476-488
DOI: 10.1002/ijc.34381 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cancer, online erschienen am 12.12.2022. Verfasst von Liliana Montella und 14 weiteren Autor:innen. Beteiligte Einrichtung: ASL NA2 NORD, Oncology Operative Unit, "Santa Maria delle Grazie" Hospital, Pozzuoli, Italy. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 95 Literaturangaben. Gefördert von: Ministero dell'Università e della Ricerca, Regione Campania, Ministry for Universities and Research.
Abstract (Originalsprache)
Glioblastoma, the most common and heterogeneous tumor affecting brain parenchyma, is dismally characterized by a very poor prognosis. Thus, the search of new, more effective treatments is a vital need. Here, we will review the druggable epigenetic features of glioblastomas that are, indeed, currently explored in preclinical studies and in clinical trials for the development of more effective, personalized treatments. In detail, we will review the studies that have led to the identification of epigenetic signatures, IDH mutations, MGMT gene methylation, histone modification alterations, H3K27 mutations and epitranscriptome landscapes of glioblastomas, in each case discussing the corresponding targeted therapies and their potential efficacy. Finally, we will emphasize how recent technological improvements permit to routinely investigate many glioblastoma epigenetic biomarkers in clinical practice, further enforcing the hope that personalized drugs, targeting specific epigenetic features, could be in future a therapeutic option for selected patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ASL NA2 NORD, Oncology Operative Unit, "Santa Maria delle Grazie" Hospital, Pozzuoli, Italy.
- CEINGE Biotecnologie Avanzate scarl, Naples, Italy.
- Department of Molecular Medicine and Medical Biotechnologies, University of Naples "Federico II", Naples, Italy.
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
- SEMM-European School of Molecular Medicine, University of Naples "Federico II", Naples, Italy.
- Institute for the Experimental Endocrinology and Oncology, Italian National Council of Research, Naples, Italy.
ORCID-Profile: Rosa Della Monica
Förderung
- Ministero dell'Università e della Ricerca
- Regione Campania
- Ministry for Universities and Research
Zitieren
APA
Montella, L., Cuomo, M., Del Gaudio, N., Buonaiuto, M., Costabile, D., Visconti, R., Di Risi, T., Vinciguerra, R., Trio, F., Ferraro, S., Bove, G., Facchini, G., Altucci, L., Chiariotti, L., & Della Monica, R. (2023). Epigenetic alterations in glioblastomas: Diagnostic, prognostic and therapeutic relevance. International Journal of Cancer, 153(3), 476-488. https://doi.org/10.1002/ijc.34381
Vancouver
Montella L, Cuomo M, Del Gaudio N, Buonaiuto M, Costabile D, Visconti R, et al. Epigenetic alterations in glioblastomas: Diagnostic, prognostic and therapeutic relevance. International Journal of Cancer. 2023;153(3):476-488. doi:10.1002/ijc.34381
BibTeX
@article{Montella2023,
author = {Montella, Liliana and Cuomo, Mariella and Del Gaudio, Nunzio and Buonaiuto, Michela and Costabile, Davide and Visconti, Roberta and Di Risi, Teodolinda and Vinciguerra, Roberta and Trio, Federica and Ferraro, Sara and Bove, Guglielmo and Facchini, Gaetano and Altucci, Lucia and Chiariotti, Lorenzo and Della Monica, Rosa},
title = {Epigenetic alterations in glioblastomas: Diagnostic, prognostic and therapeutic relevance},
journal = {International Journal of Cancer},
year = {2023},
volume = {153},
number = {3},
pages = {476--488},
doi = {10.1002/ijc.34381}
}
EUVIMED